LimmaTech Biologics
LimmaTech Biologics AG is a Swiss biotechnology company focused on developing vaccines to prevent infections caused by antimicrobial-resistant bacterial pathogens. The company applies proprietary multivalent vaccine platform approaches, enzyme-based in vivo bioconjugation, toxoid vaccine methods and engineered E. coli antigen production to advance a pipeline of clinical-stage vaccine candidates addressing pathogens such as Shigella, Klebsiella, Staphylococcus aureus and Neisseria gonorrhoeae. Headquarters and research facilities are located in Schlieren, Switzerland.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Shigella tetravalent glycoconjugate vaccine candidate (Shigella4V)
A tetravalent polysaccharide–protein conjugate vaccine candidate targeting the predominant Shigella serotypes by incorporating O-antigen polysaccharides from multiple strains; being evaluated in Phase I/II clinical studies.
Multivalent toxoid vaccine candidate for Staphylococcus aureus (LBT-SA7)
A rationally designed multivalent toxoid vaccine composed of multiple inactivated toxin components from Staphylococcus aureus intended to elicit protective immune responses against toxin-mediated disease processes.
Klebsiella vaccine candidate (clinical-stage program)
A glycoconjugate vaccine candidate against Klebsiella being evaluated in clinical development as part of the company's pipeline.
Shigella4V (S4V)
A tetravalent bioconjugate vaccine encompassing the O-antigen polysaccharides of S. flexneri 2a, 3a, 6, and S. sonnei, targeting the four predominant pathogenic Shigella serotypes.
Shigella4V
A Shigella vaccine candidate developed by LimmaTech Biologics to prevent shigellosis and address multidrug-resistant strains.
LBT-SA7
A rationally designed multivalent toxoid vaccine comprised of multiple toxoids involved in a Staphylococcus aureus infection to elicit an immune response against the pathogen's original toxins.
Shigella tetravalent glycoconjugate vaccine candidate (Shigella4V)
A tetravalent polysaccharide–protein conjugate vaccine candidate targeting the predominant Shigella serotypes by incorporating O-antigen polysaccharides from multiple strains; being evaluated in Phase I/II clinical studies.
Multivalent toxoid vaccine candidate for Staphylococcus aureus (LBT-SA7)
A rationally designed multivalent toxoid vaccine composed of multiple inactivated toxin components from Staphylococcus aureus intended to elicit protective immune responses against toxin-mediated disease processes.
Klebsiella vaccine candidate (clinical-stage program)
A glycoconjugate vaccine candidate against Klebsiella being evaluated in clinical development as part of the company's pipeline.
Shigella4V (S4V)
A tetravalent bioconjugate vaccine encompassing the O-antigen polysaccharides of S. flexneri 2a, 3a, 6, and S. sonnei, targeting the four predominant pathogenic Shigella serotypes.
Shigella4V
A Shigella vaccine candidate developed by LimmaTech Biologics to prevent shigellosis and address multidrug-resistant strains.
LBT-SA7
A rationally designed multivalent toxoid vaccine comprised of multiple toxoids involved in a Staphylococcus aureus infection to elicit an immune response against the pathogen's original toxins.
Expertise Areas
- Vaccine platform development
- Glycoengineering and bioconjugation
- Toxoid vaccine development
- E. coli-based antigen production
Key Technologies
- Enzyme-based in vivo bioconjugation
- Glycoconjugate (polysaccharide–protein) vaccines
- Toxoid vaccine technology
- Multivalent vaccine design
News & Updates
Announcement of the start of operations and establishment of headquarters and research facilities in Schlieren near Zürich.
LimmaTech Biologics announced the start of operations with headquarters and research facilities in Schlieren, Switzerland.
Received funding from a global vaccine accelerator to support development of a vaccine candidate targeting Neisseria gonorrhoeae.
Received a grant in collaboration with University Hospital of Basel to support a development program (grant referenced on company site).
Announced start of Phase I/II clinical trials for vaccine candidates including Klebsiella and Shigella programs.
Announcement of the start of operations and establishment of headquarters and research facilities in Schlieren near Zürich.
LimmaTech Biologics announced the start of operations with headquarters and research facilities in Schlieren, Switzerland.
Received funding from a global vaccine accelerator to support development of a vaccine candidate targeting Neisseria gonorrhoeae.
Received a grant in collaboration with University Hospital of Basel to support a development program (grant referenced on company site).
Announced start of Phase I/II clinical trials for vaccine candidates including Klebsiella and Shigella programs.